Relmada Therapeutics, Inc.
RLMDAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 18, 2026 | H.C. Wainwright | $12.00(+82%) | $6.60 | TheFly | |
| Mar 13, 2026 | Mizuho Securities | Uy Ear | $10.00(+69%) | $5.91 | StreetInsider |
| Jan 23, 2026 | Leerink Partners | $8.00(+102%) | $3.96 | TheFly | |
| Dec 22, 2025 | Jefferies | $9.00(+107%) | $4.35 | TheFly | |
| Jun 5, 2024 | Goldman Sachs | Andrea Tan | $2.00(-32%) | $2.95 | StreetInsider |
| Oct 13, 2022 | Jefferies | Andrew Tsai | $8.00(+24%) | $6.47 | TheFly |
| Oct 13, 2022 | Oppenheimer | Jay Olson | $7.00(+4%) | $6.75 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Mizuho | maintain | Outperform | Mar 20, 2026 |
| Leerink Partners | upgrade | Market Perform →Outperform | Jan 23, 2026 |
| Mizuho | upgrade | Neutral →Outperform | Nov 19, 2025 |
| Mizuho | downgrade | Outperform →Neutral | Dec 5, 2024 |
| Leerink Partners | downgrade | Outperform →Market Perform | Dec 4, 2024 |
| Goldman Sachs | downgrade | Neutral →Sell | Jun 5, 2024 |
| Mizuho | maintain | Buy | Jun 15, 2023 |
| SVB Leerink | maintain | Outperform | Jan 23, 2023 |
| Goldman Sachs | downgrade | Buy →Neutral | Oct 14, 2022 |
| Guggenheim | downgrade | Buy →Neutral | Oct 14, 2022 |
| Oppenheimer | downgrade | Outperform →Perform | Oct 13, 2022 |
| Goldman Sachs | maintain | Buy | Sep 23, 2022 |
| Guggenheim | maintain | Buy | Sep 6, 2022 |
| Oppenheimer | maintain | Outperform | May 9, 2022 |
| Goldman Sachs | maintain | Buy | Mar 24, 2022 |
| SVB Leerink | maintain | Outperform | Dec 20, 2021 |
| Mizuho | maintain | Buy | Nov 18, 2021 |
| Goldman Sachs | maintain | Buy | Nov 25, 2020 |
| SunTrust Robinson Humphrey | maintain | Buy | Nov 25, 2020 |
| Jefferies | maintain | Buy | Nov 25, 2020 |
| Goldman Sachs | downgrade | Buy →Neutral | Oct 28, 2020 |
| SunTrust Robinson Humphrey | maintain | Buy | May 4, 2020 |
| Goldman Sachs | maintain | Buy | Apr 21, 2020 |
| Jefferies | maintain | Buy | Jan 27, 2020 |
| Guggenheim | maintain | Buy | Dec 16, 2019 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.14| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.11 | $-0.20 | — | — |
| May 12, 2026 | $-0.22 | $-0.18 | — | — |
| Mar 19, 2026 | $-0.27 | $-0.14 | — | — |
| Nov 13, 2025 | $-0.30 | $-0.04 | — | — |
| Aug 7, 2025 | $-0.30 | $-0.25 | — | — |
| May 12, 2025 | $-0.58 | $-0.31 | — | — |
| Mar 27, 2025 | $-0.62 | $-0.70 | — | — |
| Nov 7, 2024 | $-0.72 | $-0.65 | — | — |
News
CORAL GABLES, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in London, UK, from November 16 - 19, 2026.
CORAL GABLES, Fla., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, November 12, 2026 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2026, and recent business progress.
Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation and one has
Bank of America Corp DE acquired a new stake in Relmada Therapeutics, Inc. (NASDAQ: RLMD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 812,059 shares of the company's stock, valued at approximately $5,619,000. Bank of America Corp DE owned about 0.76% of
INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.
CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.
Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.